Applications are open for the 2026 cohort!

Background Consolidative PD-L1 inhibitors after concurrent chemoradiotherapy (cCRT) have become standard care in locally advanced non-small cell lung cancer (LA-NSCLC). However, the correlation…

Ferber et al. present an autonomous artificial intelligence agent system for deployment of specialized medical oncology computational tools, validating their system across various clinical scenarios…

Trained on large and multicenter datasets with different imaging modalities, a foundation model is shown to have strong performance on the full spectrum of clinically relevant tasks and to increase…

npj Precision Oncology - Real-world performance analysis of a universal computational reasoning model for precision oncology in lung cancer

Scientific Reports - COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors

This study characterizes the three-dimensional (3D) genome architecture of 15 primary human cancer types from The Cancer Genome Atlas. The analyses identify different archetypes of enhancer usage and…

Aumolertinib is a third generation EGFR tyrosine kinase inhibitors, approved for use in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Here, the authors report a phase 2…

De novo protein design represents a fundamental pursuit in protein engineering, yet current deep learning approaches remain constrained by their narrow design scope. Here we present Pinal, a…

Introduction Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors, but they also commonly cause immune-related adverse events (irAEs).…

Background Progression from pre-cancers like ductal carcinoma in situ (DCIS) to invasive disease (cancer) is driven by somatic evolution and is altered by clinical interventions. We hypothesized that…

This prospective study conducted in a phase 3 trial has shown that pre-treatment serum VEGF-A was a negative biomarker for PFS in patients with advanced NSCLC treated with a combination of an…

Lung cancer (LC) is a leading cause of cancer-related fatalities worldwide, underscoring the urgency of early detection for improved patient outcomes. The main objective of this research is to…

Understanding evolutionary dynamics is critical for unraveling the complex progression of diseases such as cancer. Cancer evolution is inherently a temporal process driven by the accumulation of…

Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with…

In a model of pancreatic ductal adenocarcinoma, extrachromosomal DNAs are shown to be a source of high-level focal amplification driving MYC heterogeneity and phenotypic adaptation.

Background Pemetrexed is a key treatment for non-small-cell lung cancer (NSCLC), and its usage is increasing. However, owing to treatment-related fatality in a patient with severe renal impairment…

Early-onset lung cancer in young adults remains poorly studied. Here, the authors analyse the clinicopathological, molecular, and immune features of early-onset non-small cell lung cancers in a…

eISSN 2532-5264 - pISSN 1122-0643

We show the evolution of a case of EGFR mutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations,…

Immune lymphocyte estimation from nucleotide sequencing (ImmuneLENS) infers B cell and T cell fractions from whole-genome sequencing data. Applied to the 100,000 Genomes Project datasets, circulating...

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Immunotherapy, particularly PD-1 inhibitors, has revolutionized the treatment landscape for NSCLC. However, the...